Bone marrow involvement in breast cancer detected by positron emission tomography

Gupta N.C. , Maloof J. , Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37: 943–8.

Wahl R.L. , Quint L.E. , Greenough R.L. , Meyer C.R. , White R.I. , Orringer M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371–17.

Wahl R.L. , Zasadny K. , Helvie M. , Hutchins G.D. , Weber B. , Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101–11.

Niewig O.E. , Kim E.E. , Wong W.H. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920–5.

Ingle J.N. , Tormey D.C. , Tan K.H. The bone marrow examination in breast cancer: diagnostic considerations and clinical usefulness. Cancer 1978; 41: 670–4.

Mukherji S.K. , Drane W.E. , Mancuso A.A.S. , Parsons J.T. , Mendenhall W.M. , Stringer S. Occult primary tumours of the head and neck: detection with 2–(F-18) fluoro-2-deoxy-D-glucose SPECT. Radiology 1996; 199: 761–6.

Beets G. , Penninckx F. , Schiepers C. Clinical value of whole-body positron emission tomography with (18-F) fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666–70.

Hoh C.K. , Hawkins R.A. , Glaspy J.A. Cancer detection with whole-body PET using 2-(18F) fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 4: 582–9.

Shapiro C.R. , Berdon W.E. , Cohen M.D. MR imaging of diffuse bone marrow replacement in pediatric patients with cancer. Radiology 1991; 181: 587–9.

Sanal S.M. , Flickinger F.W. , Caudell M.J. , Sherry R.M. Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J Clin Oncol 1994; 12: 1415–21.

Jansson T. , Westlin J.E. , Ahlstrom H. , Lilja A. , Langstrom B. , Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?; Clin Oncol 1995; 13: 1470–7.